A. Edward Yen, MD

A. Edward Yen, MD

Baylor College of Medicine

Houston, Texas

A. Edward Yen, MD, is an Assistant Professor of Medicine in the Hematology and Oncology Section at Baylor College of Medicine in Houston, Texas. He is a practicing urologic oncologist at the Dan L Duncan Comprehensive Cancer Center and the Bladder Cancer Center at Baylor. He is also affiliated with Houston Methodist Hospital and Baylor St. Luke’s Medical Center. Dr. Yen graduated from Baylor College Of Medicine with his medical degree in 2006. His research on androgen receptors in hormone-dependent and castration-resistant prostate cancer has been published in Pharmacology & Therapeutics. His professional interests include prostate and genitourinary cancers.


Articles by A. Edward Yen, MD

Clinical Case Discussion: Metastatic Prostate Cancer and Evidence for More Precision Therapy

A. Edward Yen, MD, Assistant Professor of Medicine in the Hematology and Oncology Section at Baylor College of Medicine, introduces a metastatic prostate cancer case, and through it explores and reviews treatment options. He discusses homologous recombination and the role that it plays in DNA repair pathways, noting that 25% of patients with advanced prostate cancer have deleterious mutations in DNA damage repair genes which lead to an increased risk of prostate cancer and chance of having nodal and/or distant metastases. Dr. Yen then reviews the TRITON2 study on rucaparib in mCRPC patients with homologous recombination deficiency and the PROfound study on olaparib in mCRPC patients with homologous recombination repair alterations, both of which found a far greater response to treatment in the cohorts with the target mutations. Next, Dr. Yen discusses PARP inhibitors and their side effects, such as fatigue, nausea, pulmonary embolism, anemia, and others. Through his exploration of treatment options, Dr. Yen concludes that next-line chemotherapy is the best option for the patient given the visceral progression of their disease.

Read More

Immunotherapy For Muscle Invasive Bladder Cancer

A. Edward Yen, MD, Assistant Professor of Medicine in the Hematology and Oncology Section at Baylor College of Medicine in Houston, Texas, discusses the findings of recent immunotherapy trials for muscle invasive bladder cancer (MIBC). He explains that cisplatin-based neoadjuvant chemotherapy combinations are the current standard of care for MIBC and can provide a significant overall survival benefit, but 40 to 50% of patients are not eligible for cisplatin to begin with, and only 20% of those eligible patients actually receive cisplatin, which suggests that there are major therapeutic gaps that immunotherapies could potentially fill. Dr. Yen goes into depth on the findings of the phase II PURE-01 study of pembrolizumab, the phase II ABACUS study of atezolizumab, and the phase I NABUCCO study of nivolumab/ipilimumab, observing that all three therapies produced good responses and appeared to be correlated to different biomarkers from one another. He concludes by predicting that neoadjuvant immunotherapy will become standard of care for cisplatin-ineligible patients, but he also stresses that future studies should include higher-risk patients and should focus on predictive biomarkers.

Read More

Regionally Advanced Prostate Cancer

A. Edward Yen, MD, discusses the incidence, prognosis, and therapeutic considerations for regionally advanced prostate cancer. He defines the delineation between clinical and pathologic lymph node metastatic prostate cancers and emphasizes the importance of prescribing therapy based on individual risk factors.

Read More

Join the GRU Community

- Why Join? -